Dengue is a viral disease transmitted by infected mosquitoes. Also known as “Break-Bone Fever,” it is currently spreading rapidly: between January and September 2024, over 12.7 million cases and nearly 9,000 deaths were reported worldwide. While the highest case numbers are in the Americas region, cases are also increasing in Europe and the Eastern Mediterranean.
The EU-funded research project AVITHRAPID, through an international consortium, aims to develop antiviral treatments for emerging pandemic viral diseases such as Zika and dengue. The Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) in Hamburg, Germany, is one of the partners involved. Swiss partners of the consortium include the innovation promoter Chelonia and the State Secretariat for Education, Research, and Innovation (SERI).
Life Science Communication supports this innovative development platform with branding, social media campaigns, media relations, and the design and management of AVITHRAPID’s website.
